SCHEMBL104522

SCHEMBL104522

CC(C)c1cccc(N)c1N

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 0.48
GABRA1 P14867 3/20 0.48
TSHR P16473 3/20 0.48
GABRG2 P18507 2/20 0.48
GABRB3 P28472 2/20 0.48
GABRB2 P47870 2/20 0.48
HPGD P15428 2/20 0.48
CYP1A2 P05177 2/20 0.48
LMNA P02545 2/20 0.48
FAAH O00519 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
GABRB1 P18505 1/20 0.48
PTGS1 P23219 1/20 0.48
SLC6A2 P23975 1/20 0.48
HTR2C P28335 1/20 0.48
GABRA5 P31644 1/20 0.48
GABRA3 P34903 1/20 0.48
HTR2B P41595 1/20 0.48
GABRA2 P47869 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29407112 1.00 CYP3A4 (0.48) CYP3A4GABRA1TSHRGABRG2GABRB3
SCHEMBL104314 0.87 GABRA1 (0.55) CYP3A4GABRA1TSHRGABRG2GABRB3
SCHEMBL9818622 0.86 CYP3A4 (0.44) CYP3A4GABRA1TSHRGABRG2GABRB3
SCHEMBL992768 0.86 CD44 (0.44) CYP3A4GABRA1TSHRGABRG2GABRB3
SCHEMBL3482836 0.85 CD44 (0.48) CYP3A4GABRA1TSHRGABRG2GABRB3
Lithium Ion SCHEMBL29536467 0.84 GABRA1 (0.52) CYP3A4GABRA1TSHRGABRG2GABRB3
SCHEMBL30791052 0.84 GABRA1 (0.52) CYP3A4GABRA1TSHRGABRG2GABRB3
Hydrochloric Acid SCHEMBL8615487 0.84 GABRA1 (0.52) CYP3A4GABRA1TSHRGABRG2GABRB3
Lithium SCHEMBL30421854 0.84 GABRA1 (0.52) CYP3A4GABRA1TSHRGABRG2GABRB3
SCHEMBL6692957 0.84 GABRA1 (0.52) CYP3A4GABRA1TSHRGABRG2GABRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230374214-A1 Mixed Aromatic Amine Monomers And Polymers Thereof ExxonMobil Technology and Engineering Company (US) 2023-11-23 US claimed
EP-4225728-A1 MIXED AROMATIC AMINE MONOMERS AND POLYMERS THEREOF ExxonMobil Technology and Engineering Company (US) 2023-08-16 EP claimed
WO-2022082148-A1 MIXED AROMATIC AMINE MONOMERS AND POLYMERS THEREOF EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2022-04-21 WO claimed
US-7153631-B2 Pattern-forming process using photosensitive resin composition HITACHI CHEMICAL CO., LTD. (JP) 2006-12-26 US claimed
WO-2004096965-A1 UNSATURATED SURFACTANTS HUNTSMAN INTERNATIONAL LLC (US) 2004-11-11 WO claimed
US-5128059-A Blends of diaminoisopropylbenzene and diaminoethylbenzene FIRST CHEMICAL CORPORATION (US) 1992-07-07 US claimed
US-5075379-A Using a blend of 2,4-diamino-1-isopropylbenzene and a butadiene-acrylonitrile copolymer having secondary amine-containing end groups FIRST CHEMICAL CORPORATION (US) 1991-12-24 US claimed
US-5049639-A Synergistic, tensile strength FIRST CHEMICAL CORPORATION (US) 1991-09-17 US claimed
US-12589156-B2 Benzimidazole and benzimidazolone based protac compounds for the targeted degradation of leucine rich repeat kinase 2 (LRRK2) ARVINAS OPERATIONS, INC. (US) 2026-03-31 US disclosed
EP-4685196-A1 NEAR-INFRARED-TRANSMITTING BLACK PARTICLES, INK, AND MOLDED BODY Sekisui Chemical Co., Ltd. (JP) 2026-01-28 EP disclosed
EP-4665456-A1 BENZIMIDAZOLE AND BENZIMIDAZOLONE BASED PROTAC COMPOUNDS FOR THE TARGETED DEGRADATION OF LEUCINE RICH REPEAT KINASE 2 (LRRK2) Arvinas Operations, Inc. (US) 2025-12-24 EP disclosed
US-20250228952-A1 BENZIMIDAZOLE AND BENZIMIDAZOLONE BASED PROTAC COMPOUNDS FOR THE TARGETED DEGRADATION OF LEUCINE RICH REPEAT KINASE 2 (LRRK2) ARVINAS OPERATIONS, INC. 2025-07-17 US disclosed
US-20250196476-A1 COMPOSITION FOR VULCANIZATION BONDING, COMPOSITIONS FOR VULCANIZATION-BONDED LAMINATE, AND LAMINATE OBTAINED FROM SAID COMPOSITIONS OSAKA SODA CO., LTD. (JP) 2025-06-19 US disclosed
EP-3572464-B1 COMPOSITION FOR LAMINATE OSAKA SODA CO LTD (JP) 2025-06-04 EP disclosed
US-4106964-A Balance correction method and apparatus RANSBURG CORPORATION (US) 1978-08-15 US disclosed
US-4104236-A POLYOXYPROPYLENE GLYCOL, ACRYLONITRILE-STYRENE COPOLYMER UNION CARBIDE CORPORATION (US) 1978-08-01 US disclosed
US-4044811-A Laminated pneumatic tire THE GENERAL TIRE & RUBBER COMPANY (US) 1977-08-30 US disclosed
US-4024088-A LECITHIN UNION CARBIDE CORPORATION (US) 1977-05-17 US disclosed
US-3948829-A POLYMERIC COMPOSITION HITCO (US) 1976-04-06 US disclosed
US-3939106-A Energy absorbing polyurethane-polyurea cellular elastomers UNION CARBIDE CORPORATION (US) 1976-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250228952-A1 BENZIMIDAZOLE AND BENZIMIDAZOLONE BASED PROTAC COMPOUNDS FOR THE TARGETED DEGRADATION OF LEUCINE RICH REPEAT KINASE 2 (LRRK2) LRRK2, PINK1, PSMC1 CYP3A4 4617/4885GABRA1 2130/4885TSHR 3987/4885
US-12589156-B2 Benzimidazole and benzimidazolone based protac compounds for the targeted degradation of leucine rich repeat kinase 2 (LRRK2) LRRK2, SNCA, PARK7 CYP3A4 4739/4885GABRA1 1402/4885TSHR 3129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.